药康生物
(688046)
| 流通市值：72.32亿 | | | 总市值：72.32亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 374,808,989.09 | 170,855,596.98 | 686,837,009.6 | 509,718,216.98 |
| 营业收入 | 374,808,989.09 | 170,855,596.98 | 686,837,009.6 | 509,718,216.98 |
| 二、营业总成本 | 287,113,871.94 | 135,710,404.13 | 580,186,527.9 | 414,793,749.59 |
| 营业成本 | 133,900,946.59 | 63,123,361.52 | 261,052,207.72 | 185,294,724.73 |
| 税金及附加 | 1,639,447.13 | 965,377.16 | 3,899,209.64 | 2,341,091.34 |
| 销售费用 | 52,544,519.61 | 24,733,025.19 | 107,148,190.94 | 72,776,952.72 |
| 管理费用 | 63,520,904.6 | 30,914,953.95 | 132,536,070.83 | 97,657,073.04 |
| 研发费用 | 39,375,707.47 | 18,257,390.7 | 87,133,668.26 | 62,993,920.42 |
| 财务费用 | -3,867,653.46 | -2,283,704.39 | -11,582,819.49 | -6,270,012.67 |
| 其中:利息费用 | 2,856,768.62 | 1,077,444.95 | 4,300,850.78 | 3,348,055.67 |
| 其中:利息收入 | 4,885,223.44 | 2,229,092.48 | 14,388,671.43 | 10,897,843.98 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 372,000.14 | 1,156,726.13 | 2,341,561.65 | 2,296,950.81 |
| 加:投资收益 | 1,351,054.93 | 289,597.86 | 8,003,815.54 | 7,638,844.93 |
| 资产处置收益 | -25,422.09 | -56,116.99 | 12,516.02 | -4,740.32 |
| 资产减值损失(新) | -8,308,552.96 | -5,887,176.39 | -21,644,970.29 | -16,682,081.69 |
| 信用减值损失(新) | -8,906,176.93 | -3,174,098.09 | -3,276,607.77 | -9,507,795.12 |
| 其他收益 | 5,347,148.49 | 3,199,528.58 | 27,281,008.72 | 20,545,093.46 |
| 四、营业利润 | 77,525,168.73 | 30,673,653.95 | 119,367,805.57 | 99,210,739.46 |
| 加:营业外收入 | 0.44 | 0.01 | 14,012.15 | 4.28 |
| 减:营业外支出 | 82,948.48 | - | 166,819.78 | 11,824.73 |
| 五、利润总额 | 77,442,220.69 | 30,673,653.96 | 119,214,997.94 | 99,198,919.01 |
| 减:所得税费用 | 6,536,743.55 | 693,393.56 | 9,395,178.64 | 984,540.41 |
| 六、净利润 | 70,905,477.14 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 70,905,477.14 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 70,905,477.14 | 29,980,260.4 | 109,819,819.3 | 98,214,378.6 |
| 扣除非经常损益后的净利润 | 62,925,408.29 | 25,108,916.52 | 75,743,097.97 | 71,810,337.77 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.07 | 0.27 | 0.24 |
| (二)稀释每股收益 | 0.17 | 0.07 | 0.27 | 0.24 |
| 八、其他综合收益 | -555,105.94 | -98,315.24 | 7,553,752.88 | -198,986.15 |
| 归属于母公司股东的其他综合收益 | -555,105.94 | -98,315.24 | 7,553,752.88 | -198,986.15 |
| 九、综合收益总额 | 70,350,371.2 | 29,881,945.16 | 117,373,572.18 | 98,015,392.45 |
| 归属于母公司股东的综合收益总额 | 70,350,371.2 | 29,881,945.16 | 117,373,572.18 | 98,015,392.45 |
| 公告日期 | 2025-08-23 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |